Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3973458

Cn1c(NC2CCCCC2)nc2nc(N3CCCC(N)C3)n(Cc3ccccc3)c2c1=O.O=C(O)C(F)(F)F

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 18/20 0.56
TSHR P16473 2/20 0.49
TP53 P04637 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
FAP Q12884 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3971305 0.94 DPP4 (0.63) DPP4TSHRTP53MAPK1HSD17B10
SCHEMBL3971184 0.93 DPP4 (0.64) DPP4TSHRTP53MAPK1HSD17B10
SCHEMBL3975379 0.91 DPP4 (0.64) DPP4TSHRTP53MAPK1HSD17B10
Trifluoroacetic Acid SCHEMBL3971266 0.91 DPP4 (0.59) DPP4TSHRALDH1A1LMNAMAPT
Trifluoroacetic Acid SCHEMBL3971752 0.89 DPP4 (0.55) DPP4TSHRALDH1A1LMNAMAPT
Trifluoroacetic Acid SCHEMBL1071792 0.89 DPP4 (0.58) DPP4TSHRALDH1A1LMNAMAPT
Trifluoroacetic Acid SCHEMBL3971299 0.89 DPP4 (0.58) DPP4TSHRALDH1A1LMNAMAPT
Trifluoroacetic Acid SCHEMBL3965787 0.88 DPP4 (0.56) DPP4TSHRALDH1A1LMNAMAPT
SCHEMBL6843644 0.86 TSHR (0.53) DPP4TSHRTP53MAPK1HSD17B10
Trifluoroacetic Acid SCHEMBL3973722 0.86 DPP4 (0.62) DPP4TSHRALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569574-B2 Purine derivatives, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-08-04 US disclosed
EP-1532150-B1 NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA (DE) 2008-06-11 EP disclosed
EP-1532150-A1 NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-25 EP disclosed
US-20040122228-A1 New purine derivatives, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-06-24 US disclosed
WO-2004018469-A1 NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122228-A1 New purine derivatives, the preparation thereof and their use as pharmaceutical compositions DPP4, DPP7, DPP3 DPP4 1/4885TSHR 2158/4885TP53 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.